Physician profile
Mark B Friedman
NPI 1639221450
$8,152.15
in general payments reported to CMS, 2019-2025
35 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 80% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $460 · 2021: $1,756 · 2022: $1,281 · 2023: $1,423 · 2024: $963 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,164.05 | 2019-2024 | Grafix Pl, Collagenase Santyl, Regranex |
| Grt US Holding, INC. | $1,025.34 | 2020-2022 | |
| Horizon Therapeutics Plc | $861.63 | 2019-2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $650.53 | 2020-2025 | Nuzyra |
| Organogenesis INC. | $517.93 | 2019-2025 | Puraply, Via Matrix |
| Stryker Corporation | $483.27 | 2019-2024 | Ortholoc 2 Lapifuse, Phalinx, Easyfuse |
| Treace Medical Concepts, INC. | $391.83 | 2023-2025 | |
| Amgen INC. | $369.62 | 2024-2025 | Krystexxa |
| Kerecis Limited | $354.24 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Advanced Oxygen Therapy INC. | $329.16 | 2021-2025 | Topical Oxygen Chamber For Extremities |
| Boston Scientific Corporation | $240.29 | 2023-2025 | General - Pain Management |
| Averitas Pharma INC. | $218.34 | 2023-2025 | Qutenza |
| Tactile Systems Technology INC | $167.06 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Nevro Corp. | $154.85 | 2022 | |
| Trilliant Surgical LLC. | $150.00 | 2025 | Arsenal Ankle |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $148.43 | 2020-2023 | Exogen Ultrasound Bone Healing System |
| Crossroads Extremity Systems, LLC | $108.77 | 2019 | |
| Ossio INC | $107.48 | 2020 | |
| Melinta Therapeutics, LLC | $88.90 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $85.29 | 2024-2025 | |
| Paragon 28, INC. | $78.94 | 2019-2022 | |
| Nabriva Therapeutics, Plc | $66.42 | 2021-2022 | |
| Abbvie INC. | $51.78 | 2023 | |
| Fidia Pharma USA INC. | $51.12 | 2020-2021 | |
| Axogen | $36.88 | 2022 | |
| Dynasplint Systems INC. | $36.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.99 | 2023 | Seglentis |
| Integra Lifesciences Corporation | $29.65 | 2021 | |
| Kci USA, INC. | $28.47 | 2023 | Promogran Prisma, Activ.A.C., V.A.C. Dermatac |
| Wright Medical Technology, INC. | $27.09 | 2020 | |
| Polarityte, INC. | $26.21 | 2019 | |
| Acell, INC. | $24.09 | 2020 | |
| Cashflow Solutions, LLC | $18.31 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Arthrosurface Incorporated | $15.60 | 2019 | |
| Merck Sharp & Dohme LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.